NYMC Faculty Publications
Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia
Author Type(s)
Faculty
DOI
10.1200/JCO.20.01739
Journal Title
Journal of Clinical Oncology
First Page
3261
Last Page
3272
Document Type
Article
Publication Date
10-10-2021
Department
Medicine
Abstract
PURPOSE: Standard cytotoxic induction chemotherapy for acute myeloid leukemia (AML) results in prolonged neutropenia and risk of infection. Romyelocel-L is a universal, allogeneic myeloid progenitor cell product being studied to reduce infection during induction chemotherapy.
PATIENTS AND METHODS: One hundred sixty-three patients with de novo AML (age ≥ 55 years) receiving induction chemotherapy were randomly assigned on day 0 (d0), of whom 120 were evaluable. Subjects received either romyelocel-L infusion on d9 with granulocyte colony-stimulating factor (G-CSF) starting daily d14 (treatment group) or G-CSF daily alone on d14 (control) until absolute neutrophil count recovery to 500/µL. End points included days in febrile episode, microbiologically defined infections, clinically diagnosed infection, and days in hospital.
RESULTS: Mean days in febrile episode was shorter in the treatment arm from d15 through d28 (2.36
CONCLUSION: Subjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy.
Recommended Citation
Desai, P. M., Liu, D., & Ravandi, F. (2021). Open-Label Phase II Prospective, Randomized, Controlled Study of Romyelocel-L Myeloid Progenitor Cells to Reduce Infection During Induction Chemotherapy for Acute Myeloid Leukemia. Journal of Clinical Oncology, 39 (29), 3261-3272. https://doi.org/10.1200/JCO.20.01739
Comments
Please see the work itself for a complete list of authors.